The MarketWatch News Department was not involved in the creation of this content. Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a ...
The U.S. Food and Drug Administration (FDA) this month approved a new nasal spray therapy for acute treatment of migraine. In a press release, the biopharmaceutical company Impel NeuroPharma announced ...
RA’ANANA, ISRAEL - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech company with a market capitalization of $4.84 million, announced Tuesday that its PL-14 Allergy Blocker demonstrated over 60% ...
If you sleep next to someone who snores you know that the endless horking and honking isn’t very fun… and it makes the snorer’s life even worse. Some students and doctors in Baltimore, Maryland, ...
RA’ANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotechnology company with a market capitalization of $11 million and currently rated as having WEAK financial health according to InvestingPro ...
The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of ...
Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon” or the "Company”), a biotechnology company focusing on the development of intranasal products, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback